Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses

Archives of Dermatology

Volumn 143, Issue 6, 2007, Pages 736-740

  Utikal, Jochen ^a,d,e   Ugurel, Selma ^a,b   Kurzen, Hjalmar ^a   Erben, Philipp ^a   Reiter, Andreas ^a   Hochhaus, Andreas ^a   Nebe, Thomas ^a   Hildenbrand, Ralf ^a   Haberkorn, Uwe ^c   Goerdt, Sergij ^a   Schadendorf, Dirk ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMATINIB; PLATELET DERIVED GROWTH FACTOR B;

ADULT; ARTICLE; BONE MARROW; CASE REPORT; CELL INFILTRATION; HISTIOCYTE; HUMAN; LIVER; MALE; PRIORITY JOURNAL; ROSAI DORFMAN DISEASE; SKIN INFILTRATE; SPLEEN; SYSTEMIC DISEASE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX;

EID: 34250718661     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.6.736     Document Type: Article

References (20)

1. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004;1:283-296.
2. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45:256-264.
3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990; 7:19-73.
4. Goerdt S, Kolde G, Bonsmann G, et al. Immunohistochemical comparison of cutaneous histiocytoses and related skin disorders: diagnostic and histogenetic relevance of MS-1 high molecular weight protein expression. J Pathol. 1993; 170:421-427.
5. Utikal J, Klemke CD, Gratchev A, Goerdt S. Cutaneous non-Langerhans' cell histiocytoses. J Dtsch Dermatol Ges. 2003;1:471-491.
6. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16:53-59.
7. Cross NC, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma. 1993;11:39-43.
8. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
9. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827-832.
10. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186-189.
11. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-1832.
12. Jones RL, Judson IR. The development and application of imatinib. Expert Opin Drug Saf. 2005;4:183-191.
13. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001; 358:1421-1423.
14. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
15. Menzel C, Hamscho N, Dobert N, et al. PET imaging of Rosai-Dorfman disease: correlation with histopathology and ex-vivo beta-imaging. Arch Dermatol Res. 2003;295:280-283.
16. Harik L, Nassar A. Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma. Arch Pathol Lab Med. 2006; 130:1223-1226.
17. Dewar AL, Domaschenz RM, Doherty KV, et al. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia. 2003;17:1713-1721.
18. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127-3132.
19. Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006;25:147-151.
20. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004;351:1034-1035.